Talk:KRAS

message: I think a specific example illustrating the function would be very helpful. (For example, a demonstration of the role of KRAS in the best-studied function.) Is there a way to formally request something like this from domain experts? Neuroschizl (talk) 00:28, 2 May 2016 (UTC)
thread_title: Function

message: CLinical significance section says EGFR inhibitors are effective against most wild-type KRAS negative [colon] cancers, but what treatments are targeted at the mutated KRAS (positive) cancers ? Rod57 (talk) 13:35, 15 November 2010 (UTC)
thread_title:  KRAS positive 

message: Hi,
My name is Carole Welsch and i am Associate Director, Personalized Heathcare at QIAGEN Inc. I would like to contribute to this page and share some recent information that will help update the KRAS Wikipedia page to make it more accurate. In July 2012, the FDA approved a companion diagnostic KRAS test for the drug Erbitux. As a consequence, the drug label was updated to require the use of an FDA approved KRAS test prior to prescribing the drug.
Therefore, i would like to suggest the following addition to the existing page. For your convenience, i have also referenced each statement with third party source.
Under the “KRAS testing” section which currently reads: “In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbitux)) indicated for treatment of metastatic colorectal cancer to include information about KRAS mutations.[17]”
I would like to suggest adding: “In 2012, the FDA also cleared QIAGEN’s therascreen KRAS test, which is a genetic test designed to detect the presence of seven mutations in the KRAS gene in colorectal cancer cells. This test is used to aid physicians in identifying patients with metastatic colorectal cancer for treatment with Erbitux. The presence of KRAS mutations in colorectal cancer tissue indicates that the patient may not benefit from treatment with Erbitux. If the test result indicates that the KRAS mutations are absent in the colorectal cancer cells, then the patient may be considered for treatment with Erbitux.”
[Reference: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312055.htm]
I look forward to hearing back from you.
Best regards,
Carole
Carolewelsch (talk) 20:11, 26 November 2012 (UTC)
replies: text: seems ok. Added as above Wiki CRUK John (talk) 11:16, 20 June 2014 (UTC)
thread_title:  Requested update 

message: PDB in picture is not KRas. It is farnesyltransferase with 11 residues of Kras as the substrate,  — Preceding unsigned comment added by 141.211.201.244 (talk) 06:01, 27 May 2014 (UTC)
replies: text: You are right. Seems like nobody noticed until even now. I've just created a 3D rendering of KRAS (based on PDB ID 3GFT) and put it in the infobox. SPLETTE :] How's my driving? 05:22, 16 November 2016 (UTC)
thread_title: Image

message: I think it would be useful to include a pronunciation of the word 'KRAS'. I have heard it pronounced as both KAY-ras and as kras, one syllable. We use the former. It would help prevent misunderstandings.
Kernos (talk) 15:14, 2 July 2014 (UTC)
thread_title:  Pronunciation 

message: Hello fellow Wikipedians,
I have just added archive links to  on KRAS. Please take a moment to review my edit. If necessary, add  after the link to keep me from modifying it. Alternatively, you can add  to keep me off the page altogether. I made the following changes:
*Added archive https://web.archive.org/20141109174052/http://www.oncogenetics.org/web/fda-updates-vectibix-and-erbitux-labels-with-kras-testing-info to http://www.oncogenetics.org/web/fda-updates-vectibix-and-erbitux-labels-with-kras-testing-info
When you have finished reviewing my changes, please set the checked parameter below to true to let others know.
Cheers.—cyberbot IITalk to my owner:Online 10:38, 22 February 2016 (UTC)
thread_title:  External links modified 

message: If a mutated version of the protein KRAS is pulled to the surface of cancer cells, then the drug-KRAS complex acts as an "eat me" flag that marks cancer cells for destruction by the immune system. 82.50.120.164 (talk) 09:19, 19 September 2022 (UTC)
thread_title:  Waiting for a secondary source (reviewed articles)..